REG-4basebio Plc: 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial

4BasebioAnnouncement

Today 07:00

4basebio PLC

("4basebio" or the "Company")

4basebio Signs Clinical Supply Agreement                                      
                                    to                                        
                                  Support Phase II                            
                                              Clinical Trial
*                                                                             
                     Oncology focused biotech to utilise 4basebio’s opDNA®
technology to support Phase II clinical trial of immunotherapy candidate      
                                                                              
     
*                                                                             
                      Multi-year, seven-figure revenue stream reflecting
increased commercial momentum
CAMBRIDGE, UK –                                                             
             20 May                                                           
               2026                              – 4basebio PLC (AIM:
4BB), a company pioneering an enzymatically-produced DNA technology serving
the next generation genetic medicines markets, announces that it has signed a
Clinical Supply Agreement with a leading cancer immunotherapy innovator
(“the Client”) to provide GMP-grade opDNA® starting material for its
latest clinical programme.

Under the terms of the agreement, 4basebio will supply synthetic DNA to be
used as a critical material for the Client’s immunotherapy candidate for an
upcoming Phase II clinical trial. The agreement is expected to provide an
approximate seven-figure revenue stream over the next 12 months, reflecting
4basebio’s unique capability to provide a safer, cost-effective replacement
for plasmid DNA in the development of genetic medicines.

By leveraging 4basebio’s enzymatic, cell-free manufacturing process, the    
                                       Client will enhance                    
                       the safety of its therapeutic product by fully
eliminating microbial contamination and the inclusion of antibiotic resistance
genes, helping to                                            accelerate its
development timelines from sequence to clinic                                 
         .

Dr. Amy Walker, Chief Executive Officer at 4basebio, added                    
                                                     : “This partnership
demonstrates how our proprietary DNA technology platform can help clients
overcome complex manufacturing hurdles and bring safer and effective therapies
to patients. We continue to see growing interest in our DNA molecules across
the genetic medicine space and are delighted to support our partners through
their clinical trials.”

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:                                        
                             
 

 4basebio PLC                                                       
 			Dr Amy Walker, CEO                                              
 			+44 (0)12 2396 7943                                             
                                                                    
 Cairn Financial Advisers LLP (Nominated Adviser)                   
 			Jo Turner / Sandy Jamieson / Ed Downes                          
 			+44 (0)20 7213 0880                                             
                                                                    
 Cavendish Capital Markets Limited (Joint Broker)                   
 			Geoff Nash / Nigel Birks                                        
 			+44 (0)20 7220 0500                                             
                                                                    
 RBC Capital Markets (Joint Broker)                                 
 			Kathryn Deegan / Matthew Coakes                                 
 			+44 (0)20 7653 4000                                             
                                                                    
 ICR Healthcare (Media and Investor Relations)                      
 			Mary-Jane Elliott / Jessica Hodgson                             
 			+44 (0)203 707 5700                                             
                                                                    

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces
GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.

For more information, visit                                                   
                       4basebio.com (https://www.4basebio.com/)               
                                                          .

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio. Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved